Loading…
Loading grant details…
| Funder | European Commission |
|---|---|
| Recipient Organization | Universite de Strasbourg |
| Country | France |
| Start Date | May 03, 2022 |
| End Date | May 02, 2024 |
| Duration | 730 days |
| Number of Grantees | 1 |
| Roles | Coordinator |
| Data Source | European Commission |
| Grant ID | 101028461 |
Bacterial antibiotic resistance has become a massive threat to the public health.
The situation with the opportunistic pathogen P.aeruginosa is particularly worrying because this major cause of nosocomial infections in immunocompromised patients becomes resistant to nearly all antibiotics available. Pyocin S2 is a bacteriocin, a natural protein able to kill several P.aeruginosa strains.
The pyocin highjacks a nutrient transport system of the bacteria to get across the cell envelop.
My project aims to develop chimeric bacteriocin-antibiotic conjugates to overcome the resistance mechanisms of P.aeruginosa by combining the vector potency of the pyocin and the bacteriotoxic activity of known synthetic antibiotics.
Using the bacteriocin as a Trojan horse will be beneficial because: i) the active uptake of the drug; ii) reduced susceptibility to the efflux-mediated resistance; iii) specific targeting the pathogenic bacteria in the presence of healthy commensal microbiota.
Preliminary results with organic fluorophores have revealed the feasibility of the pyocin S2-mediated vectorization of small molecules.
In my work I will combine synthetic chemistry, biochemistry, microbiology and pharmacology approaches to synthesise defined antibiotic-pyocin conjugates and to create a new class of antibacterial molecules urgently needed in the post-antibiotic era.
Universite de Strasbourg
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant